TB CAB

TB CAB: Open letter to the European Medicines Agency

Open letter to the European Medicines Agency regarding the filing of the drugs delamanid and bedaquiline for market approval.

Read More →

TB CAB, TAG open letter to Janssen regarding the FDA approval of bedaquiline

Determining a fair and affordable price of bedaquiline is essential for timely approval and appropriate domestic and global access to the best possible therapeutic options for people with DR-TB.

Read More →

Round table discussion: Activist engagement and community involvement in TB research

3rd Annual South African TB Conference, Durban 2012
Date: 14 June 2012
Time: 14h00 – 15h30
Location: Hall 3B

Read More →

TB CAB: Open letters to drug companies and FDA on delanamid and bedaquiline

Open letters to Otsuka, Janssen Pharmaceutical Companies of Johnson & Johnson, Food and Drug Administration and European Medicines Agency.

Read More →

TB CAB: Open letter

Open letter regarding Cepheid pricing of the GeneXpert machines and cartridges for high-burden settings in the public and private sectors.

Read More →

TB CAB: Open letter

Open letter to the Medicines Control Council and Ministry of Health on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa.

Read More →

Page 4 of 4 · Total posts: 6

←First 3 4